Works by Rink-Jan Lohman

Results: 17

Exploring the therapeutic potential of an antinociceptive and anti-inflammatory peptide from wasp venom.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-38828-w

By:

Galante, Priscilla;
Campos, Gabriel A. A.;
Moser, Jacqueline C. G.;
Martins, Danubia B.;
dos Santos Cabrera, Marcia P.;
Rangel, Marisa;
Coelho, Luiza C.;
Simon, Karina S.;
Amado, Veronica M.;
de A. I. Muller, Jessica;
Koehbach, Johannes;
Lohman, Rink-Jan;
Cabot, Peter J.;
Vetter, Irina;
Craik, David J.;
Toffoli-Kadri, Monica C.;
Monge-Fuentes, Victoria;
Goulart, Jair T.;
Schwartz, Elisabeth F.;
Silva, Luciano P.

Publication type:

Article

Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function.

Published in:

Frontiers in Pharmacology, 2016, v. 7, p. 1, doi. 10.3389/fphar.2016.00355

By:

Gruber, Staci A.;
Sagar, Kelly A.;
Dahlgren, Mary K.;
Racine, Megan T.;
Smith, Rosemary T.;
Lukas, Scott E.;
Hammer, Ronald P.;
Lohman, Rink-Jan

Publication type:

Article

Pharmacological inhibition of protease‐activated receptor‐2 reduces crescent formation in rat nephrotoxic serum nephritis.

Published in:

Clinical & Experimental Pharmacology & Physiology, 2019, v. 46, n. 5, p. 456, doi. 10.1111/1440-1681.13077

By:

Han, Yingjie;
Tian, Lifang;
Ma, Frank;
Tesch, Greg;
Vesey, David A.;
Gobe, Glenda C.;
Lohman, Rink‐Jan;
Morais, Christudas;
Suen, Jacky Y.;
Fairlie, David P.;
Nikolic‐Paterson, David J.

Publication type:

Article

Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a.

Published in:

Nature Communications, 2017, v. 8, n. 1, p. 1, doi. 10.1038/s41467-017-00414-w

By:

Lohman, Rink-Jan;
Hamidon, Johan K.;
Reid, Robert C.;
Rowley, Jessica A.;
Yau, Mei-Kwan;
Halili, Maria A.;
Nielsen, Daniel S.;
Junxian Lim;
Wu, Kai-Chen;
Zhixuan Loh;
Do, Anh;
Suen, Jacky Y.;
Iyer, Abishek;
Fairlie, David P.

Publication type:

Article

Flexibility versus Rigidity for Orally Bioavailable Cyclic Hexapeptides.

Published in:

ChemBioChem, 2015, v. 16, n. 16, p. 2289, doi. 10.1002/cbic.201500441

By:

NielsEN, Daniel S.;
Lohman, Rink ‐ Jan;
Hoang, Huy N.;
Hill, Timothy A.;
Jones, Alun;
Lucke, Andrew J.;
Fairlie, David P.

Publication type:

Article

Improving on Nature: Making a Cyclic Heptapeptide Orally Bioavailable.

Published in:

Angewandte Chemie International Edition, 2014, v. 53, n. 45, p. 12059, doi. 10.1002/anie.201405364

By:

Nielsen, Daniel S.;
Hoang, Huy N.;
Lohman, Rink‐Jan;
Hill, Timothy A.;
Lucke, Andrew J.;
Craik, David J.;
Edmonds, David J.;
Griffith, David A.;
Rotter, Charles J.;
Ruggeri, Roger B.;
Price, David A.;
Liras, Spiros;
Fairlie, David P.

Publication type:

Article

Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy.

Published in:

Frontiers in Pharmacology, 2023, v. 14, p. 1, doi. 10.3389/fphar.2023.1150313

By:

Lohman, Rink-Jan;
Tupally, Karnaker Reddy;
Kandale, Ajit;
Cabot, Peter J.;
Parekh, Harendra S.

Publication type:

Article

Improving on Nature: Making a Cyclic Heptapeptide Orally Bioavailable.

Published in:

Angewandte Chemie, 2014, v. 126, n. 45, p. 12255, doi. 10.1002/ange.201405364

By:

Nielsen, Daniel S.;
Hoang, Huy N.;
Lohman, Rink ‐ Jan;
Hill, Timothy A.;
Lucke, Andrew J.;
Craik, David J.;
Edmonds, David J.;
Griffith, David A.;
Rotter, Charles J.;
Ruggeri, Roger B.;
Price, David A.;
Liras, Spiros;
Fairlie, David P.

Publication type:

Article

Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition.

Published in:

Communications Biology, 2020, v. 3, n. 1, p. 1, doi. 10.1038/s42003-020-01504-0

By:

Kennedy, Amanda J.;
Sundström, Linda;
Geschwindner, Stefan;
Poon, Eunice K. Y.;
Jiang, Yuhong;
Chen, Rongfeng;
Cooke, Rob;
Johnstone, Shawn;
Madin, Andrew;
Lim, Junxian;
Liu, Qingqi;
Lohman, Rink-Jan;
Nordqvist, Anneli;
Fridén-Saxin, Maria;
Yang, Wenzhen;
Brown, Dean G.;
Fairlie, David P.;
Dekker, Niek

Publication type:

Article

Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists.

Published in:

Scientific Reports, 2016, p. 24575, doi. 10.1038/srep24575

By:

Seow, Vernon;
Lim, Junxian;
Cotterell, Adam J.;
Yau, Mei-Kwan;
Xu, Weijun;
Lohman, Rink-Jan;
Kok, W. Mei;
Stoermer, Martin J.;
Sweet, Matthew J.;
Reid, Robert C.;
Suen, Jacky Y.;
Fairlie, David P.

Publication type:

Article

Protease‐activated receptor 2 does not contribute to renal inflammation or fibrosis in the obstructed kidney.

Published in:

Nephrology, 2019, v. 24, n. 9, p. 983, doi. 10.1111/nep.13635

By:

Ma, Frank Y;
Han, Yingjie;
Ozols, Elyce;
Chew, Phyllis;
Vesey, David A;
Gobe, Glenda C;
Morais, Christudas;
Lohman, Rink‐Jan;
Suen, Jacky Y;
Johnson, David W;
Fairlie, David P;
Nikolic‐Paterson, David J

Publication type:

Article

High Cell Permeability Does Not Predict Oral Bioavailability for Analogues of Cyclic Heptapeptide Sanguinamide A*.

Published in:

Australian Journal of Chemistry, 2020, v. 73, n. 4, p. 344, doi. 10.1071/CH19479

By:

Nielsen, Daniel S.;
Lohman, Rink-Jan;
Hoang, Huy N.;
Fairlie, David P.;
Hill, Timothy A.

Publication type:

Article

Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe.

Published in:

Frontiers in Pharmacology, 2014, v. 5, p. 1, doi. 10.3389/fphar.2014.00261

By:

Patiño-Rodríguez, Omar;
Torres-Roque, Irma;
Martínez-Delgado, Maricela;
Escobedo-Moratilla, Abraham;
Pérez-Urizar, José;
Lohman, Rink-Jan;
Leggio, Gian Marco

Publication type:

Article

Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.

Published in:

Frontiers in Pharmacology, 2014, v. 5, p. 1, doi. 10.3389/fphar.2014.00240

By:

Woodhead, Jeffrey L.;
Kyunghee Yang;
Siler, Scott Q.;
Watkins, Paul B.;
Brouwer, Kim L. R.;
Barton, Hugh A.;
Howel, Brett A.;
Maggi, Adriana;
Lohman, Rink-Jan

Publication type:

Article

A novel inhibitor of class IIa histone deacetylases attenuates collagen‐induced arthritis.

Published in:

British Journal of Pharmacology, 2024, v. 181, n. 23, p. 4804, doi. 10.1111/bph.17306

By:

Poon, Eunice K.;
Liu, Ligong;
Wu, Kai‐Chen;
Lim, Junxian;
Sweet, Matthew J.;
Lohman, Rink‐Jan;
Iyer, Abishek;
Fairlie, David P.

Publication type:

Article

Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism.

Published in:

FASEB Journal, 2013, v. 27, n. 12, p. 4757, doi. 10.1096/fj.13-232702

By:

Junxian Lim;
Abishek Iyer;
Ligong Liu;
Suen, Jacky Y.;
Rink-Jan Lohman;
Vernon Seow;
Mei-Kwan Yau;
Brown, Lindsay;
Fairlie, David P.

Publication type:

Article

An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats.

Published in:

FASEB Journal, 2012, v. 26, n. 7, p. 2877, doi. 10.1096/fj.11-201004

By:

Lohman, Rink.-Jan;
Cotterell, Adam J.;
Barry, Grant D.;
Liu, Ligong;
Suen, Jacky Y.;
Vesey, David A.;
Fairlie, David P.

Publication type:

Article